Lycia Therapeutics, Inc. priced its initial public offering at $18.00 a share, offering 17,640,000 shares of common stock, to list on the Nasdaq Global Select Market under the symbol LYCA. It filed a Form S-1 registration statement for an initial public offering on October 5, 2026. As of November 4, 2026, its final prospectus is on file (Form 424B4, October 23, 2026).
Sell to companies like Lycia Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Lycia Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-10-05. It has amended it 1 time. It filed its final prospectus on 2026-10-23, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Lycia Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Venrock Healthcare Capital Partners III, L.P. | 11.9% of the class | 5%+ stakes | Source |
| June 25, 2026 | Form D, private offering | $75M sold | Form D page | Source |
Check before you invest in Lycia Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Lycia Therapeutics, Inc. and the records around it.
Lycia Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026), X4 Pharmaceuticals, Inc. (Sep 2026)
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q4 2026, newest first.
- Anthropic, PBC (Nov 2026)
- Iambic Therapeutics, Inc. (Oct 2026)
Watch Lycia Therapeutics, Inc.
Get an email when Lycia Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lycia Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lycia Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lycia Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “LYCA.”From the 424B4 filed 2026-10-23
Shares offered
We are offering 17,640,000 shares of our common stock.From the 424B4 filed 2026-10-23
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2026-10-23
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance the clinical development of our IgE portfolio consisting of LCA-0061 and LCA-0062, to advance clinical development of our Graves’ disease program, LCA‑0321, and to advance our other research and development activities; as well as for working capital and for other general corporate purposes.From the 424B4 filed 2026-10-23
Net loss or income
For the year ended December 31, 2025 and the six months ended June 30, 2026, we reported a net loss of $36.5 million and $19.2 million, respectively.From the S-1/A filed 2026-10-20
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-10-05 | Registration statement filed | S-1 |
| 2026-10-20 | Registration statement amended | S-1/A |
| 2026-10-23 | Final prospectus filed: the offering is priced | 424B4 |
Lycia Therapeutics, Inc.'s full funding historyFounders and team
Tools for this story
Each opens in a new tab, filled in for Lycia Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.